RE:RE:RE:EU Legislative proposals aims to expedite new medicinesLast week's international adoption of the expedited approval process of biologics drugs that address orphan diseases and those diseases (i.e. cancers) with "unmet treatment needs" , while collectively providing these biological drugs with 13 years of marketing exclusivity in the US, EU and the UK, Roche's acquisition of marketing approval in Canada for TecentriqSC could now serve as a significant catalyst for the acquisition of ONCY and then towards the international approval of ONCY's pelareorep in combination with immune checkpoint inhibitors, PLUS pelareorep's combination with bispecifcs, ADCs, CAR-T therapy, and small molecules like PARP and CDK 4/6 inhibitors. for example.
https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-inc?postid=36003279